GlassScriptPhysician profile
Justin Babbel
NPI 1922531003
$5,355.76
in general payments reported to CMS, 2019-2025
24 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $67.74 · 2021: $950 · 2022: $681 · 2023: $1,061 · 2024: $1,072 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,548 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,548.28 |
| Education | $108.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,192.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $978.87 | 2022-2025 | Fasenra, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $457.13 | 2020-2025 | Cuvitru, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $440.96 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $380.58 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Alk-Abello, INC | $352.12 | 2021-2022 | |
| Csl Behring | $188.71 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Pharming Healthcare, INC. | $160.42 | 2023-2025 | Ruconest |
| Amgen INC. | $155.80 | 2023-2025 | Tezspire |
| Genentech, INC. | $150.00 | 2022 | |
| Biocryst US Sales Co., LLC | $119.40 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $118.37 | 2021-2024 | Auvi-Q |
| Grifols USA, LLC | $118.27 | 2022 | |
| Organon LLC | $108.03 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $99.45 | 2025 | Neffy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $69.82 | 2025 | |
| Cycle Pharmaceuticals INC | $53.30 | 2025 | Sajazir |
| Lilly USA, LLC | $50.28 | 2025 | Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.90 | 2020-2023 | Spiriva Respimat |
| Abbvie INC. | $36.55 | 2023-2025 | Rinvoq |
| Ionis Pharmaceuticals, INC. | $27.38 | 2025 | Dawnzera |
| Pfizer INC. | $23.03 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.69 | 2025 | Alvesco |
| Blueprint Medicines Corporation | $14.18 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Babbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.